Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCT-601 in Advanced Solid Tumors
NCT03700294Phase 1Terminated
- Sponsor
- ADC Therapeutics
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mipasetamab uzoptirine in breast cancer, colorectal cancer (CRC), esophageal cancer and 7 more, sponsored by ADC Therapeutics. Primary endpoints: Dose Limiting Toxicity at 42 days and Maximum Tolerated Dose up to 2 years. Started Dec 2018; status: terminated.
02
Drugs
mipasetamab uzoptirine
03
Conditions
breast cancercolorectal cancer (CRC)esophageal cancergastric cancer (GC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT03700294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03700294.